參考文獻/References:
[1]王永云，靳文，俞蘭．胃癌相關基因及靶向治療的研究進展[J]．醫(yī)學綜述，2020，26（19）:3814-3819.[2]Song Z，Wu Y，Yang J，et al．Progress in the treatment of advanced gastric cancer[J]．Tumour Biol，2017，39(7):1010428317714626.[3]Yung-Jue B，Eric Van C，Andrea F，et al．Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3，open-label，randomised controlled trial[J]．The Lancet，2010，376(9742):687-697．[4]Kohei S，Yoshitaka H，Yasushi O，et al．Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma:a subgroup analysis of the GATSBY study[J]．Asia-Pacific Journal of Clinical Oncology，2020，16(1):5-13.[5]沈源，保麗玲，吳桂霞，等.淋巴管密度、微血管密度與VEGF在胃癌中的生物學意義[J].暨南大學學報：自然科學與醫(yī)學版，2018，39（3）:223-228.[6]Xu Z Y，Hu C，Chen S Q，et al．Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil[J]．Cancer management and research，2019，11:4905-4915.[7]Yang Y，Wu X W，Li F F，et al．Evaluation of efficacy and safety of apatinib treatment in advanced gastric cancer[J]．Journal of cancer research and therapeutics，2019，15(2):365-369.[8]時越.雷莫蘆單抗治療晚期胃癌的研究現(xiàn)狀[J].現(xiàn)代醫(yī)學，2017，45（2）:314-316．[9]Huang H．Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: recent advances[J]．Sensors (Basel，Switzerland)，2018，18(10):3249.[10]Shah M A，Starodub A，Sharma S，et al．Andecaliximab/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: results from a phase I study[J]．Clinical cancer research : an official journal of the American Association for Cancer Research，2018，24(16):3829-3837.[11]Sahin U,Koslowski M,Dhaene K，et al．Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development[J]．Clin Cancer Res，2008，14(23):7624-34.[12]Baek J H，Park D J，Kim G Y，et al．Clinical Implications of claudin18.2 expression in patients with gastric cancer[J]．Anticancer research，2019，39(12):6973-6979.[13]Jiang H，Shi Z，Wang P，et al．Claudin18.2-Specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer[J]．Journal of the National Cancer Institute，2019，111(4):409-418.[14]韋煒，蔣敬庭，吳昌平.胃癌中PD-L1的表達及PD-1/PD-L1抑制劑應用研究進展[J].臨床檢驗雜志，2017，35（5）:363-365.[15]凌佳音，韓濤，潘海邦，等.納武利尤單抗治療晚期胃癌臨床研究進展[J].中國腫瘤臨床，2020，47（15）:792-797.[16]Kelly R J．Immunotherapy for esophageal and gastric cancer[J]．Am Soc Clin Oncol Educ Boo,2017,37:292-300.[17]Boku N，Ryu M H，Kato K，et al．Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated,unresectable,advanced,or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized，phase II trial (ATTRACTION-4)[J]．Ann Oncol,2019,30(2):250-258.[18]Kanae E，Osamu H，Yusuke M，et al．Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways[J]．Cancer science，2016，107(4):391-397.[19]宋一萌，李明真，馬潞林.花生四烯酸代謝產(chǎn)物與腫瘤發(fā)生和發(fā)展的研究進展[J].臨床泌尿外科雜志，2017，32（3）:236-240.[21]Yuan-Chuen W，Kai-Ming H．In vitro anti-inflammatory effect of apigenin in the Helicobacter pylori-infected gastric adenocarcinoma cells[J]．Yuan-Chuen Wang;Kai-Ming Huang，2013，53:376-83.[22]Min L，Aixin S，Hongxian P，et al． Safety,tolerability,and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects[J]．Journal of Ethnopharmacology，2014，156:210-215.